首頁 › 子宮內膜癌 › 加州 › San Francisco
San Francisco, CA 的 子宮內膜癌 臨床試驗
14 項針對 子宮內膜癌 的研究正在 San Francisco（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Kaiser Permanente-San Francisco, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Kaiser Permanente-San Francisco, San Francisco
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
招募中3 期
- CPMC Research Institute, San Francisco
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- University of California, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- UCSF Medical Center-Mission Bay, San Francisco
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
招募中1/2 期
- University of California San Francisco Cancer Center, San Francisco
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
招募中2 期
- 014, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
招募中1/2 期
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
招募中2 期
- University of California, San Francisco (UCSF), San Francisco
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
招募中1 期
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, San Francisco
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Columbus, OH25 項研究
- Chicago, IL25 項研究
- Oklahoma City, OK25 項研究
San Francisco 的其他研究
- 前列腺癌45 項研究
- 乳癌43 項研究
- 非小細胞肺癌36 項研究
- 癌症（所有類型）35 項研究
- 心臟衰竭29 項研究
- 轉移性癌症28 項研究
- 肺癌22 項研究
- 黑色素瘤22 項研究
- 胰臟癌20 項研究
- 卵巢癌19 項研究
- 大腸直腸癌18 項研究
- 心血管疾病18 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。